澳华内镜(688212) - 2024 Q4 - 年度业绩预告

Revenue Forecast - The company expects 2024 annual revenue to be between 730.50 million and 754.36 million CNY, an increase of 52.42 million to 76.28 million CNY, representing a year-on-year growth of 7.73% to 11.25%[4]. - The previous year's revenue was 678.08 million CNY, with a net profit of 57.85 million CNY and a net profit after deducting non-recurring gains and losses of 44.49 million CNY[6]. - The increase in overseas market access and business expansion contributed to revenue growth, while domestic business revenue growth was limited due to a decrease in procurement activities[8]. Profit Forecast - The projected net profit attributable to shareholders for 2024 is expected to be between 15.73 million and 23.38 million CNY, a decrease of 34.47 million to 42.12 million CNY, reflecting a year-on-year decline of 59.59% to 72.81%[4]. - The company anticipates a net profit attributable to shareholders after deducting non-recurring gains and losses to be between -12.74 million and -5.09 million CNY for 2024[4]. - Non-recurring gains and losses are expected to impact the net profit attributable to shareholders by approximately 28.47 million CNY, primarily from government subsidies and investment income[8]. Marketing and Expenses - The company has been enhancing its marketing system and brand influence, leading to increased sales, management, and R&D expenses, which grew faster than revenue[8]. Uncertainties and Forecast Validity - The company has not identified any significant uncertainties affecting the accuracy of this earnings forecast[9]. - The forecast data is preliminary and subject to change pending the audited annual report for 2024[10].